
Clarity Pharmaceuticals Granted Breakthrough Therapy Designation for Prostate Cancer Copper Theranostic
Clarity Pharmaceuticals wins FDA breakthrough status for prostate cancer PET agent 64Cu-SAR-bisPSMA, a major milestone for its copper theranostic program.



